AnaptysBio (ANAB)
(Delayed Data from NSDQ)
$37.75 USD
+0.46 (1.23%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $37.77 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$37.75 USD
+0.46 (1.23%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $37.77 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
AnaptysBio (ANAB) Plunges on Lead Candidate Study Failure
by Zacks Equity Research
AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.
AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio (ANAB) Jumps: Stock Rises 7.7%
by Zacks Equity Research
AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
AnaptysBio Shares Up on Positive Top-Line Psoriasis Data
by Zacks Equity Research
AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -5.33% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio, Inc. (ANAB) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ANAB) Outperforming Other Medical Stocks This Year?
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ANAB) Outperforming Other Medical Stocks This Year?
Will AnaptysBio Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor AnaptysBio
Is AnaptysBio (ANAB) Stock a Solid Choice Right Now?
by Zacks Equity Research
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AnaptysBio Enters Oversold Territory
by Zacks Equity Research
AnaptysBio has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -2.68% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AnaptysBio, Inc. (ANAB) Q3 Earnings Expected to Decline
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for October 31st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 31st
AnaptysBio (ANAB) Looks Good: Stock Adds 8.1% in Session
by Zacks Equity Research
AnaptysBio (ANAB) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
What Makes AnaptysBio, Inc. (ANAB) a New Strong Buy Stock
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Will AnaptysBio Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in AnaptysBio.
All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AnaptysBio (ANAB) Looks Good: Stock Adds 9.9% in Session
by Zacks Equity Research
AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Options Traders Expect Huge Moves in AnaptysBio (ANAB) Stock
by Zacks Equity Research
AnaptysBio (ANAB) needs investors to pay close attention to the stock based on moves in the options market lately.
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 19.72% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for AnaptysBio (ANAB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AnaptysBio (ANAB) stock based on the movements in the options market lately.